Month: June 2023

The CCI ETH course provides law enforcement and AML professionals with the necessary skills to navigate the intricate realm of Ethereum, which is widely recognized as the virtual computer of the world. VANCOUVER, British Columbia, June 12, 2023 (GLOBE NEWSWIRE) — BIGG Digital Assets Inc. (“BIGG” or the “Company”)(CSE: BIGG; OTCQX: BBKCF; WKN: A2PS9W), owner of Blockchain Intelligence Group (blockchaingroup.io) (“BIG”), a leading developer of blockchain technology search, risk-scoring and cryptocurrency and digital asset training, is proud to announce the latest release of its renowned Certified Cryptocurrency Investigator (CCI) training program; CCI ETH. This new certificate course aims to empower investigators with the knowledge and tools needed to understand and conduct complex technical investigations...

Beijing, June 12, 2023 (GLOBE NEWSWIRE) —  Kuke Music Holding Limited (“Kuke” or the “Company”) (NYSE: KUKE), a leading classical music service platform in China with approximately 3 million audio and video music tracks, announced the establishment of a new operating center in Wuhan, the capital city of Hubei Province, China. Kuke Music plans to relocate its marketing and technology departments to the Wuhan operating center. As a significant transportation hub and economic center in China, Wuhan boasts a well-developed transportation network and excellent infrastructure, which will facilitate the company’s connections with various regions across the country. Additionally, Wuhan offers relatively reasonable operating costs, abundant talent resources, and high-quality educational institutions, providing...

Dr. McKinnell joins the Nexcella, Inc. Board of Directors with 35 years of experience at Pfizer, Inc., including 6 years as Chairman and Chief Executive Officer Dr. McKinnell is a former independent director of ChemoCentryx, acquired by Amgen for $3.7 billion in 2022 and former Chairman/CEO of Optimer Pharmaceuticals, acquired by Cubist (now Merck & Co.) for $535 million in 2013LOS ANGELES, June 12, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that effective today, Henry A. McKinnell, Jr, Ph.D., former Chairman and Chief Executive Officer of Pfizer Inc., has been appointed to the Company’s Board of Directors. Dr. McKinnell brings significant leadership to Nexcella: developing, launching and commercializing drug candidates; building world-class...

ŽEMAITIJOS PIENAS, AB (hereinafter – the Company) entered into a business loan transaction with SEB bankas, under which the Company is granted a business loan of 12 millions 135.2 thousand euros.The purpose of the loan is the construction of wind turbines with all secondary items, appurtenances, and/or engineering equipment and facilities in Skurvydiškė Village, Telšiai District Municipality. Arnas MatuzasHead of Legal E-mail: a.matuzas@zpienas.lt 

“Vilvi Group”, which consists of Vilkyškių pieninė AB, “Modest” AB, Kelmės pieninė AB, “Kelmės pienas” UAB, “Pieno logistika” AB and “Baltic Dairy Board” SIA, consolidated sales for May 2023 amounted to 15.66 million EUR 24% decrease comparing to May 2022. The sales of the Group for period January – May 2023 amounted to 85.48 million EUR 5.6% decrease comparing to the same period last year. Vilija Milaseviciute Economics and finance directorPhone: +370 441 55 102

SEATTLE, June 12, 2023 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully enrolled. EVANGELINE is a randomized non-inferiority trial of Atossa’s patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. The PK run-in cohort consists of six patients, all of whom will be treated with (Z)-endoxifen at 40mg/day...

Publication Reviews Certain Receptor-Protein Interactions.Provides Overview of Basic Science Supporting Simufilam.Published in Drug Development Research, a Peer-Reviewed Journal.AUSTIN, Texas, June 12, 2023 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced a new science publication in Drug Development Research, a peer-reviewed journal. This article reviews certain receptor-protein interactions, including an overview of basic science supporting simufilam. Simufilam is Cassava Sciences’ oral investigational drug candidate that is currently in Phase 3 clinical trials in patients with mild-to-moderate Alzheimer’s disease dementia. “This paper highlights the role of altered filamin A and its receptor interactions in Alzheimer’s...

IR-Med, Inc. PressureSafe deviceEarly detection of pressure injuries can be challenging for minority populations due to the current method of visual inspection Patients with dark skin tones suffered more than twice as much as those with lighter skin, evidencing a major health inequality in the U.S. Dr. Dalton, a visionary healthcare thought leader and hall of fame CEO, is supporting IR-Med in analyzing the benefits of the PressureSafe device for African American and Hispanic populations in the U.S.Rosh Pina, Israel, June 12, 2023 (GLOBE NEWSWIRE) — IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven spectrographic analysis technology platform to address significant healthcare needs, today reiterated its commitment to healthcare equality globally and particularly in the U.S. Pressure...